Guggenheim analyst Michael Schmidt downgraded Fate Therapeutics to Neutral from Buy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FATE:
- What’s In Store for Fate Therapeutics Heading into 2023?
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Fate Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Fate Therapeutics initiated with a Sell at Goldman Sachs
- Cantor biotech/biopharma analysts hold an analyst/industry conference call